<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978688</url>
  </required_header>
  <id_info>
    <org_study_id>MVT-601-1001</org_study_id>
    <nct_id>NCT04978688</nct_id>
  </id_info>
  <brief_title>Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants</brief_title>
  <official_title>A Randomized Open Label Study to Evaluate the Safety, PK, and PD of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy for 6 Weeks in Healthy Premenopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, open-label, repeat dose study of once daily relugolix alone or&#xD;
      relugolix combined with hormonal add-back therapy (combination estradiol/norethindrone&#xD;
      acetate) (E2/NETA) to assess safety, including markers of bone resorption, pharmacokinetics&#xD;
      (PK), and pharmacodynamics (PD) endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2016</start_date>
  <completion_date type="Actual">September 21, 2016</completion_date>
  <primary_completion_date type="Actual">September 21, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK: Area Under The Concentration-Time Curve From Time Zero To Hour 24 (AUC0-24) Of Relugolix, E2, Estrone (El), Ethinylestradiol (EE), NETA</measure>
    <time_frame>Predose and up to 24 hours at Weeks 3 and 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Concentration (Cmax) Of Relugolix, E2, El, NETA</measure>
    <time_frame>Predose and up to 24 hours at Weeks 3 and 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time To Maximum Concentration (Tmax) Of Relugolix, E2, El, EE, NETA</measure>
    <time_frame>Predose and up to 24 hours at Weeks 3 and 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum Follicle Stimulating Hormone (FSH) At Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum Luteinizing Hormone (LH) At Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum Progesterone (P) At Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum E2 And E1 At Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In N-telopeptide And C-telopepetide Concentrations At Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Treatment-Emergent Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Hot Flush</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Relugolix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received relugolix 40 milligrams (mg) alone for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relugolix + E2/NETA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relugolix</intervention_name>
    <description>Administered as an oral tablet once daily.</description>
    <arm_group_label>Relugolix</arm_group_label>
    <arm_group_label>Relugolix + E2/NETA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/NETA</intervention_name>
    <description>Administered as an oral tablet once daily.</description>
    <arm_group_label>Relugolix + E2/NETA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pre-menopausal female between 18 and 48 years of age.&#xD;
&#xD;
          2. E2, P, LH and FSH concentrations within 0.5x of the lower limits of normal range and&#xD;
             2x of the upper limits of normal upper limits of normal range (ULN)&#xD;
&#xD;
          3. Regular menstrual periods for the 3 months prior to study enrollment&#xD;
&#xD;
          4. Body weight â‰¥ 45 killograms (kgs) and body mass index (BMI) of 20 to 36&#xD;
&#xD;
          5. Capable of giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Lactating Females&#xD;
&#xD;
          3. Any contraindication to the treatment with E2 and NETA&#xD;
&#xD;
          4. Use of the following medications in the 3 months prior to screening: injectable&#xD;
             hormonal contraceptives, sex hormone medications or danazol&#xD;
&#xD;
          5. Use of the following medications in the 6 months prior to screening: injectable&#xD;
             gonadotropin-releasing hormone agonists, hormonal, or non-hormonal intrauterine&#xD;
             devices&#xD;
&#xD;
          6. History of sensitivity to any of the study medications of components thereof or&#xD;
             history of drug&#xD;
&#xD;
          7. Significant gynecological, endocrine, metabolic or other health conditions&#xD;
&#xD;
          8. History of regular alcohol consumption within 6 months of study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Relugolix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

